What Mastical D Unidia treats: main uses and benefits

Mastical D Unidia is designed to provide dual support for patients at risk of combined calcium and vitamin D deficiency, focusing on structural integrity and mineral balance. This combination is generally relevant for deficiency treatment and supportive therapy in chronic bone conditions.

Supportive Therapy and Deficiency Correction

This medicine is commonly used to help with the prevention and treatment of systemic deficiency of both calcium and Vitamin D, and as an adjunct to specific treatment of established osteoporosis. Correcting these deficits helps stabilize the body's calcium balance, which is important for multiple physiological functions. The therapeutic support provided by this combination may assist with preserving bone integrity and managing conditions like skeletal fragility, osteomalacia, and hypocalcemia. It is often applied in scenarios where postmenopausal women or the elderly have an increased risk of fracture due to inadequate mineral status.

“The primary goal is the long-term support of skeletal health and the prevention of mineral-related complications.”

This therapeutic effect may assist with managing symptoms related to severe hypocalcemia, such as neuromuscular excitability or the involuntary muscle contractions of latent tetany. By contributing to easing the overall symptom load, it supports the normal function of muscles and nerves.

---

Quick Fact: Relief for Skeletal Fragility The supplement is considered relevant in conditions where symptoms of low bone mineral density and increased fracture risk are present due to underlying calcium and Vitamin D deficiency.

Official Eligibility and Non-Eligibility Status

The eligibility profile for Mastical D Unidia (Calcium Carbonate and Colecalciferol) is defined by official regulatory labeling, establishing strict rules for who can and cannot use the medicine.

Eligibility Scope	Official Regulatory Status
Populations Allowed	Adults and Older Adults requiring treatment or prevention of calcium and Vitamin D deficiency.
Contraindicated Populations	Patients with Hypercalcaemia (high blood calcium), Hypercalciuria (high urine calcium), Hypervitaminosis D, or Severe Renal Impairment.
Age-Related Rules	Use is not intended or not recommended for Children and Adolescents.
Conditional Use Required	Use in Pregnancy and Lactation is permitted only for deficiency correction, subject to strict total daily Vitamin D limits.
Condition-Specific Restrictions	Contraindicated in patients with a history of kidney stones (nephrolithiasis). Caution is required in patients with Sarcoidosis or those on prolonged immobilisation.

---

Eligibility Severity Classification

The regulatory basis for non-eligibility includes Absolute Contraindication for metabolic disorders (e.g., Hypercalcaemia) and Use Not Recommended for specific age groups (e.g., children). Use is also restricted by renal function, with severe renal impairment being an absolute contraindication.

The official regulatory documentation for Mastical D Unidia outlines interaction patterns that primarily involve two mechanisms: the physical reduction of drug absorption in the digestive tract and systemic effects on mineral balance.

Co-administration with this medicine may reduce the systemic exposure of several crucial agents, necessitating mandatory separation of doses. These agents include tetracycline and quinolone antibiotics, as well as drugs such as bisphosphonates and levothyroxine (thyroid hormones). For these combinations, regulatory bodies require strict timing rules, often mandating that the other medicine be taken two to six hours apart from this supplement.

---

Interaction Type	Interacting Agent Examples	Official Description of Outcome
Pharmacodynamic	Cardiac Glycosides, Thiazide Diuretics	Increased risk of hypercalcaemia or drug toxicity; requires close monitoring.
Metabolic	Phenytoin, Barbiturates	Reduction in the effectiveness of Vitamin D via increased metabolic activation.

---

Additionally, consumption of foods containing oxalic acid (e.g., spinach, rhubarb) or phytic acid (e.g., whole cereals) is documented to reduce calcium absorption and also requires a time separation. Co-administration of other calcium or Vitamin D supplements is restricted due to the combined risk of hypercalcaemia. Special consideration for monitoring is noted in elderly patients concurrently taking cardiac glycosides or diuretics.

Modulation of Intestinal Calcium Absorption

Mastical D Unidia's mechanism involves the modulation of key pathways in calcium and phosphate metabolism. The cholecalciferol component is hydroxylated to its active form, calcitriol (1,25-(OH)2D3). Calcitriol acts as an agonist for the Vitamin D Receptor (VDR), a nuclear receptor. This engagement promotes gene transcription that regulates enterocyte transport proteins, increasing the small intestine's capacity for dietary calcium and phosphate uptake. This intracellular cascade facilitates the transfer of minerals across the intestinal wall, thereby influencing systemic mineral availability.

---

Regulation of Bone Mineral Metabolism

The components influence skeletal dynamics by affecting mineral concentration and cellular activity. Calcium acts as a fundamental mineral input for the skeletal matrix. Systemic calcitriol regulates the activity of bone-remodeling cells (osteoblasts and osteoclasts), influencing the dynamic equilibrium between bone formation and resorption. This process affects the concentration of minerals within the skeletal matrix.

---

Engagement in Parathyroid Hormone Feedback Regulation

Increased serum calcium and calcitriol levels constitute a negative feedback signal to the parathyroid glands. This signal suppresses the synthesis and release of Parathyroid Hormone (PTH). Reducing PTH concentration diminishes the downstream signaling effects of this mediator, resulting in an altered homeostatic feedback within the endocrine axis that governs mineral metabolism.

Administration and Dosage

Mastical D Unidia is an oral medicine, supplied as a chewable tablet, and is solely administered by the oral route. The proper administration method requires the tablet to be chewed or sucked and not swallowed whole.

---

Standard Dosing Regimens

The standard regimen for adults, including older adults, is one chewable tablet once daily. Each tablet provides a fixed dose of 1000 mg elemental calcium and 800 IU Colecalciferol (Vitamin D3). This daily intake is generally intended for long-term support as an adjunct to established treatments or for deficiency prevention. The medicine can be taken at any time, with or without food.

Usage Instruction	Detail
Frequency	Once daily
Intake Method	Must be chewed or sucked
Missed Dose	Skip the missed dose; do not take a double dose

---

Specific Administration Constraints

Administration must follow specific procedural timing constraints to ensure proper absorption and effectiveness. Certain medications, such as tetracycline antibiotics and quinolone antibiotics, must be taken 4-6 hours and 6 hours, respectively, apart from the Mastical D Unidia dose. Regarding patient demographics, the product is not intended for use in children and adolescents. Furthermore, use is generally restricted in patients with severe kidney impairment to adhere to safety considerations.

Research Evidence / Overview of Studies for Mastical D Unidia

---

Evidence for Correcting Combined Calcium and Vitamin D Deficiency

Research has explored the use of this combination in adults and older adults who have documented patterns of systemic or functional imbalance related to both calcium and Vitamin D levels. The evidence base includes short-term Randomized Controlled Trials (RCTs) and open-label studies, as well as information gathered under regulatory frameworks concerning established medical use. This research primarily examined specific circulating biochemical markers, such as serum 25( OH) D (which tracks Vitamin D status) and parathyroid hormone (PTH) levels.

Studies report how symptoms evolved in the observed populations by exploring patterns related to the movement of these markers. Research has explored the evaluation of mineral status using this combination. Studies reported patterns where the levels of Vitamin D and PTH were observed in patients during the measurement period. However, the research so far indicates that the studies largely focus on short-term changes in these measured biochemical levels.

---

Evidence as Adjunct Therapy for Osteoporosis

Research has explored the use of this combination as supportive therapy alongside specific anti-osteoporosis prescription medicines. This evidence is primarily derived from large-scale, long-term Randomized Controlled Trials (RCTs), as well as systematic reviews and meta-analyses that track skeletal events. Research examined outcomes reflecting daily functioning or activity level, such as the incidence of fractures and changes in Bone Mineral Density (BMD).

Studies monitored whether the combination was associated with changes in the rate of skeletal events when compared to a non-active substitute in these major trials. Findings describe patterns observed in the studies regarding skeletal event rates in certain groups, such as institutionalized patients. However, the certainty remains low in some areas. The evidence quality varies across studies and the findings were mixed when evaluating broad groups of community-dwelling older adults who did not have an established, severe deficiency prior to the study.

---

What Is Still Uncertain in the Research

The available evidence highlights several areas where research is ongoing or where data are still emerging. The research landscape shows that findings were mixed regarding fracture prevention in wide groups of community-dwelling older adults who are not severely deficient. Furthermore, research describes that the effect of the combination may vary based on the specific baseline Vitamin D and calcium status of the patient at the start of the study. Evidence highlights what is known—and what is still uncertain—about these varying response patterns.

Common questions about Mastical D Unidia (FAQ)

---

Q: What is Mastical D Unidia used for?

A: Mastical D Unidia is typically indicated for the treatment and prevention of calcium and Vitamin D3 deficiency. It may be used as a supplement alongside specific treatments for osteoporosis when a patient has a diagnosed risk of this deficiency.

---

Q: When is the best time of day to take this supplement?

A: The recommended instructions for use suggest that it may be taken at any time of the day, preferably with a meal. Consistency is key, and it's best to follow the administration advice provided by your healthcare professional or the product information leaflet.

---

Q: Can Mastical D Unidia be taken with other medications?

A: Interactions are possible with various medications, particularly antibiotics (like tetracyclines or quinolones) and certain cardiac medications (like digitalis). It is important to inform your healthcare provider about all medicines you are currently taking, including over-the-counter supplements, to manage potential interaction risks.

How to Store and Dispose of Mastical D Unidia?

The official storage conditions for this medicine vary based on its packaging, but all formulations must be kept out of the sight and reach of children.

Packaging Type	Maximum Storage Temperature	Protection Requirements
Plastic Bottle	Do not store above 30^circC	Store in original container, keep tightly closed to protect from light and moisture.
Blister Pack	Do not store above 25^circC	Store in original package and outer carton to protect from light and moisture.

Do not use the chewable tablets after the expiry date (EXP). The medicine must not be thrown away via wastewater or household waste. Official regulatory instructions require that unused or expired product be returned to a pharmacist for disposal, as these measures help protect the environment.